On December 8, the new crown monoclonal neutralizing antibody developed by the team of Zhang Linqi, a professor at Tsinghua University School of Medicine , was approved by the China National Medical Products Administration. This is also China’s first fully self-developed and effective anti-coronavirus specific drug that has undergone strict randomized, double-blind, and placebo-controlled studies.
[wpdiscuz-feedback id=”gp2njjfdnm” question=”What do you think about this ?” opened=”1″][/wpdiscuz-feedback]
It is used to treat adults and adolescents (≥12 years old, weight ≥40 kg) patients who have a positive test result for the new coronavirus (SARS-CoV-2) and who have progressed to severe COVID-19 risk factors.
Zhang Linqi said that the drug can provide treatment and prevention effects, and one shot can last for 9 months or even 1 year.